Cite
HARVARD Citation
Zorzi, A. et al. (n.d.). A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Pediatric blood & cancer. 60 (11), pp. 1868-1874. [Online].